Tsai Lab Team

Dr. Tsai completed a postdoctoral fellowship at Massachusetts General Hospital and Harvard Medical School, a PhD in Functional Genomics and a master’s degree in bioinformatics from North Carolina State University. Dr. Tsai is an Associate Member in the Department of Hematology where his research program focuses on developing genome editing technologies for therapeutics. His group has recently developed CHANGE-seq, a state-of-the-art, sensitive, unbiased, high-throughput method for defining the genome-wide activity of genome editors.

In 2020, Dr. Tsai was chosen as one of the American Society for Gene and Cell Therapy Outstanding New Investigators. He is a co-chair of the Steering Committee of the NIH Somatic Cell Genome Editing Consortium and a key contributor to the St. Jude Collaborative Research Consortium for Sickle Cell Disease (CRC-SCD).